Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6371347 | 0.94 | MAPK14 (0.89) | MAPK14GAAALDH1A1MEN1LMNA | |
| SCHEMBL6288420 | 0.88 | MAPK14 (1.00) | MAPK14ALDH1A1MEN1LMNAPOLB | |
| SCHEMBL6288429 | 0.86 | MAPK14 (0.76) | MAPK14GAA | |
| SCHEMBL6378516 | 0.85 | MAPK14 (0.74) | MAPK14GAA | |
| SCHEMBL6370766 | 0.85 | MAPK14 (0.74) | MAPK14GAA | |
| SCHEMBL6371723 | 0.84 | MAPK14 (0.72) | MAPK14GAAALDH1A1KMT2A | |
| SCHEMBL6376427 | 0.83 | MAPK14 (0.71) | MAPK14GAA | |
| SCHEMBL6371738 | 0.81 | MAPK14 (0.69) | MAPK14GAA | |
| SCHEMBL6234554 | 0.81 | MAPK14 (1.00) | MAPK14ALDH1A1 | |
| SCHEMBL6291906 | 0.79 | MAPK14 (0.65) | MAPK14GAAALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256122-A1 | Substituted pyridazinones | PHARMACIA CORPORATION | 2005-11-17 | — | — | US | claimed |
| US-20050020594-A1 | Substituted pyridazinones | PHARMACIA CORPORATION | 2005-01-27 | — | — | US | claimed |
| US-20040142932-A1 | Substituted pyridazinones | PHARMACIA CORPORATION | 2004-07-22 | — | — | US | claimed |
| US-20050256122-A1 | Substituted pyridazinones | PHARMACIA CORPORATION | 2005-11-17 | — | — | US | disclosed |
| US-20050020594-A1 | Substituted pyridazinones | PHARMACIA CORPORATION | 2005-01-27 | — | — | US | disclosed |
| US-20040142932-A1 | Substituted pyridazinones | PHARMACIA CORPORATION | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142932-A1 | Substituted pyridazinones | MAP4K2, MAPK6, MAP3K6 | MAPK14 29/4885GAA 920/4885ALDH1A1 1889/4885 |
| US-20050020594-A1 | Substituted pyridazinones | MAP4K2, MAPK6, MAP3K6 | MAPK14 34/4885GAA 956/4885ALDH1A1 2217/4885 |
| US-20050256122-A1 | Substituted pyridazinones | MAP4K2, MAPK6, MAP3K6 | MAPK14 34/4885GAA 956/4885ALDH1A1 2217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.